To the Editor We read with great interest the Brief Report by Treister et al1 published in a recent issue of JAMA Dermatology. We applaud the authors’ initiative to investigate this important topic because practitioners and the public lack sufficient information on the predisposing factors for dupilumab-associated conjunctivitis (DAC).
Dupilumab is a new drug, and we are continuing to learn about its potential and adverse effects. While conjunctivitis was a significant adverse event occurring in 3% to 14% of patients with atopic dermatitis (AD) who received biweekly dupilumab treatments in phase 3 trials (vs <1%-8% in the placebo cohorts),2,3 no significant increased risk of conjunctivitis associated with dupilumab was observed in asthma trials (2.3% in the dupilumab cohort vs 3.3% in the placebo cohort).4 In dupilumab pivotal trials in AD, conjunctivitis was either patient reported or dermatologist assessed rather than ophthalmologist evaluated.
Hendricks AJ, Shi VY. Learning About Dupilumab-Associated Conjunctivitis. JAMA Dermatol. 2019;155(6):754. doi:10.1001/jamadermatol.2018.5951
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: